These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23250689)

  • 21. Use of aripiprazole for psychosis and agitation in dementia.
    Laks J; Miotto R; Marinho V; Engelhardt E
    Int Psychogeriatr; 2006 Jun; 18(2):335-40. PubMed ID: 16255839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
    Devanand DP; Mintzer J; Schultz S; Sultzer D; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Andrews H; Levin B
    Am J Geriatr Psychiatry; 2012 Apr; 20(4):362-73. PubMed ID: 21407047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients.
    Lee YM; Park JM; Lee BD; Moon E; Jeong HJ; Chung YI; Kim JH; Kim HJ; Mun CW; Kim TH; Kim YH
    J Clin Psychiatry; 2016 Jan; 77(1):e8-13. PubMed ID: 26845282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of the agitation of late-life psychosis and Alzheimer's disease.
    Salzman C
    Eur Psychiatry; 2001 Jan; 16 Suppl 1():25s-28s. PubMed ID: 11520475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
    Khan BU
    J Autism Dev Disord; 1997 Aug; 27(4):479-89. PubMed ID: 9261670
    [No Abstract]   [Full Text] [Related]  

  • 26. Agitation and psychosis in dementia.
    Ballard C
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):913-7. PubMed ID: 17974863
    [No Abstract]   [Full Text] [Related]  

  • 27. Response to Carnahan.
    Lopez OL; Becker JT
    Am J Psychiatry; 2014 Feb; 171(2):227-8. PubMed ID: 24500461
    [No Abstract]   [Full Text] [Related]  

  • 28. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
    Barak Y; Plopski I; Tadger S; Paleacu D
    Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
    Mowla A; Pani A
    J Clin Psychopharmacol; 2010 Feb; 30(1):40-3. PubMed ID: 20075646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using risperidone for Alzheimer's dementia-associated psychosis.
    McNeal KM; Meyer RP; Lukacs K; Senseney A; Mintzer J
    Expert Opin Pharmacother; 2008 Oct; 9(14):2537-43. PubMed ID: 18778191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
    Mintzer J; Greenspan A; Caers I; Van Hove I; Kushner S; Weiner M; Gharabawi G; Schneider LS
    Am J Geriatr Psychiatry; 2006 Mar; 14(3):280-91. PubMed ID: 16505133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
    Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
    Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical antipsychotic agents ineffective for AD.
    Duke Med Health News; 2007 Jan; 13(1):8. PubMed ID: 17299888
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
    Oguma T; Jino K
    Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
    Tune LE
    J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
    Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
    Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of risperidone on nursing burden associated with caring for patients with dementia.
    Asghar Ali AA; Espinoza R; Kavirajan H; Read S
    J Am Geriatr Soc; 2005 Jul; 53(7):1261-2; author reply 1262-3. PubMed ID: 16108953
    [No Abstract]   [Full Text] [Related]  

  • 39. To prescribe or not to prescribe? Atypical antipsychotic drugs in patients with dementia.
    Jeste DV; Meeks T
    South Med J; 2007 Oct; 100(10):961-3. PubMed ID: 17943030
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.